Loading data for AVR — first visit, this takes a few seconds.
Anteris Technologies Global Corp.
8.52 +0.17 (2.04%)
- Рыночная капитализация
- $839.1M
- Объём торгов
- 70.9K
- Следующая дата отчётности
- Nov 12, 2026
Anteris Technologies Global Corp. (AVR): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $1.01M | n/a | +63.27% |
| EPS | -$0,30 | -$0,09 | +50.82% |
Метрики
- Бид
- 5.95
- Выручка (TTM)
- 2.24M
- Чистая прибыль (TTM)
- -104M
- n/a
- -1.95
- n/a
- -8.61
- P/B (TTM)
- 3.34
- P/S (TTM)
- 373.83
- Дата отчёта
- Nov 12, 2026
- Аск
- 10.57
- Объём торгов
- 70,925
- Ср. объём (20д)
- 1,044,620
- Открытие
- 8.32
- Пред. закрытие
- 8.35
- Диапазон дня
- 8.26 - 8.60
- Диапазон за 52 недели
- 3.30 - 11.05
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании Anteris Technologies Global Corp.
Профиль →Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Отрасль Medical Devices
Сектор Healthcare
Дата IPO Dec 13, 2024
Сотрудники 174
Биржа NasdaqGM
Тикер AVR